Deflazcort
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Here is a comprehensive overview of Deflazacort based on authoritative medical textbooks:
Deflazacort
Drug Class & Mechanism
Deflazacort is a heterocyclic glucocorticoid prodrug (oxazoline derivative of prednisolone) with both anti-inflammatory and immunosuppressive properties. It is converted to its active metabolite (21-desacetyl-deflazacort) after oral administration. Like other glucocorticoids, it acts by modulating gene transcription via intracellular glucocorticoid receptors, suppressing pro-inflammatory cytokines and stabilizing lysosomal membranes.
FDA-Approved Indication
Duchenne Muscular Dystrophy (DMD) — approved for patients ≥5 years of age (brand name: Emflaza).
Clinical Evidence in DMD
- In a multi-center, placebo-controlled phase 3 trial (196 children with DMD), deflazacort was compared to prednisone and placebo for 12 weeks:
- At 12 weeks: deflazacort showed greater improvement in muscle strength vs. placebo.
- At 52 weeks: muscle strength was significantly better in the deflazacort group compared to the prednisone group.
- A meta-analysis confirmed deflazacort's superiority over prednisone in DMD for muscle strength outcomes.
- Glucocorticoids (including deflazacort) change the natural history of DMD by:
- Prolonging independent ambulation
- Preserving cardiac and pulmonary function in the teenage years
- Preventing severe scoliosis
- Improving survival (steroid use >1 year: 9% mortality vs. 19% in those on steroids <1 month over 10 years)
Dosing
- Deflazacort dose equivalent to prednisone 0.75 mg/kg/day is the standard reference dose for DMD.
- The optimal prednisone dose is 0.75 mg/kg/day; deflazacort is dosed on an equivalent anti-inflammatory basis (deflazacort ~1 mg ≈ prednisone 0.75 mg in anti-inflammatory potency).
Other Uses (Off-label / Investigational)
| Condition | Context |
|---|---|
| Minimal Change Disease (nephrotic syndrome) | Tried as an alternative steroid formulation; mixed results reported |
| Distal ureteral stones | Combined with nifedipine (calcium channel blocker) to reduce edema and facilitate spontaneous stone passage |
| Dermatology | Used as an alternative to prednisolone/dexamethasone in certain inflammatory skin conditions |
Adverse Effects
Long-term glucocorticoid side effects apply:
- Weight gain / obesity
- Osteoporosis (calcium 1200–1500 mg/day + vitamin D supplementation recommended for all patients on glucocorticoids)
- Metabolic syndrome
- Mood swings and behavioral changes — one of the primary reasons for therapy discontinuation in DMD
- Gastrointestinal disturbances
- Adrenal suppression (extended tapering schedules recommended to prevent adrenal insufficiency)
- Memory effects — acute steroid use may reversibly impair long-term memory; effects may be dose-dependent
Compared to prednisone, deflazacort may have a relatively lower weight gain profile, which is one reason it is preferred in some DMD patients.
Cardiac Considerations in DMD
A retrospective analysis confirms steroid benefit (including deflazacort) to the heart in DMD patients. Cardiomyopathy management in DMD includes ACE inhibitors, beta-blockers, and aldosterone antagonists. Deflazacort is part of the multi-disciplinary Care Considerations guidelines for DMD.
Future Directions
Deflazacort/prednisone are not curative. A novel dissociative steroid, vamolorone, is under investigation with promising early results — potentially offering anti-inflammatory benefits with fewer steroid side effects.
Sources:
- Fishman's Pulmonary Diseases and Disorders, p. 1510
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry, p. 2027–2028
- Braunwald's Heart Disease, p. 1214
- Adams and Victor's Principles of Neurology, 12th Ed., p. 1415
- National Kidney Foundation Primer on Kidney Diseases, 8e
- Harriet Lane Handbook, 23rd Ed.
This is a shared conversation. Sign in to Orris to start your own chat.